MountView Therapeutics is a biopharmaceutical company developing next generation tranformative technologies for gene and drug delivery targeting vascular endothelium for treatment of human diseases.
The proprietary nanoparticle delivery platform is the next generation of gene delivery technology targeting the vascular endothelium without gene size limitation. It can deliver CRISPR/Cas9, and other genome editors and any transgene(s) in a regulatable, organ and cell-specific manner and modulate 1 or more genes simultaneously for treatment of various diseases caused by endothelial dysfunction including cardiovscular diseases, hypertension, pulmonary artery hypertension, severe sepsis, acute respiratory distress syndrome, cancer, and cancer metastasis.
Precision gene targeting makes one's endothelium forever young and rejuvenates one's aged endothelium for better life.
Transformative endothelium-targeted regulatable gene therapy: Precise and Effective.
The biotech team also provides nanoaprticle products for biomedical research to disrupt and/or overexpress gene(s) in vascular endothelial cells of mice and rats.